EPHA2 and pancreatic neoplasm: Furthermore, the combination of EphA2 and CA19-9 detected 96/97 (99.0%) patients with pancreatic cancer, 4/5 (80.0%) patients with early-stage pancreatic cancer, and 76/77 (98.7%) patients with late-stage pancreatic cancer.